KLISBio key facts
as of Oct 2026- Developer of an innovative medical technology designed to find new tissue regeneration methods.
- KLISBio is valued at approximately $34.9M as of Oct 2026 (last reported valuation).
- It has raised $27.3M; the latest was Later Stage VC ($15.7M) in Jan 2025.
- Notable investors include European Innovation Council, CDP Venture Capital (Rome), Primo Capital (Milano), Anya Capital, Enea Tech e Biomedical — 15 tracked in total.
- Status: Privately Held (backing).
KLISBio's last reported valuation, Dec 2022. Nothing priced has surfaced since.
- ·The complete investor list: 15 names
- ·Watch KLISBio: the Monday email on marks, rounds and moves
KLISBio funding rounds
No funding rounds for KLISBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs KLISBio
15+KLISBio valuation
KLISBio's last reported valuation was $34.9 million in Dec 2022. No priced round, secondary trade or fund mark has surfaced since.
KLISBio investors
15 investors are on record for KLISBio, including European Innovation Council, CDP Venture Capital (Rome), Primo Capital (Milano) and Anya Capital.
About KLISBio
Developer of an innovative medical technology designed to find new tissue regeneration methods. The company's technology offers silk-based bio-materials that help to regenerate human tissues, including those present in the vascular system, and then to degrade and be safely absorbed in the body, enabling medical research companies to develop products harnessing the power of nano-fibers and use them for the treatment of tissue-related diseases.
- Sector
- Healthcare
- HQ
- Milan, Italy
- Founded
- 2014
- Employees
- 21
- Website
- klis.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.